Grifols's extensive plasma derivatives safety program includes a rigorous methodology, cutting edge technologies, experienced staff and full traceability from plasma donation to final product  (www.pedigrionline.net ).  From donor to patient.

• More than 80 Grifols-owned donation centers   (http://plasmacenters.grifols.com/ )
  Our commitment.
• Qualified donors
  All donors thoroughly screened and tested.

• Identification and verification by barcodes
  Full traceability from donation to final product.
• Immunoassay (ELISA) testing for each donation
  Each unit is tested by enzyme linked immunoabsorbent assay (ELISA) for HBsAg, HIVAb, and HCVAb. ELISA is a serologic test that links a measurable enzyme to virus antibodies or antigens.
• Minipool Nucleic Acid Testing (NAT)
  Each unit is screened using Nucleic Acid Amplification Testing (NAT) for HIV-1 and HCV after pooling small aliquots from not more than 512 units (minipool). NAT is a highly sensitive test that can detect small virus amounts.
• Inventory-hold and look-back
  Every unit of plasma is held in inventory for at least 60 days before being released into production.
• Final computer verification
  The only way plasma is released.

• ELISA and NAT testing in fractionation pool
  As an added safety measure.
• Pathogen elimination steps
  For maximum safety of the final product.
• Specialized staff continuously updating their skills and expertise
  Confidence in a product requires trust in the people who make it.
• Specific product biochemical features and formulation
  To enhance the safety profile.

• Unique laser etched identifier number
  Helps deter tampering.
• Pharmacovigilance